Cargando…

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)

Transfusional iron overload in patients with chronic anemias can result in multiple organ failure. Experience in the management of iron overload in patients with myelodysplastic syndromes is limited, as many do not receive chelation therapy due to short-life expectancy and the difficulties associate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Tucci, Anna Angela, Murru, Roberta, Alberti, Daniele, Rabault, Bertrand, Deplano, Simona, Angelucci, Emanuele
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2007
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974812/ https://www.ncbi.nlm.nih.gov/pubmed/17391307 http://dx.doi.org/10.1111/j.1600-0609.2007.00840.x

Ejemplares similares

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
por: Porter, John, et al.
Publicado: (2008)

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
por: Vini, Dimitra, et al.
Publicado: (2011)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Renal Function in Patients with Thalassemia Major Receiving Exjade(®) Dispersible Tablets and a New Film-coated Tablet Formulation of Deferasirox (Nanojade(®))
por: Falahati, Vahid, et al.
Publicado: (2022)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
por: Lisette, Del Corso, et al.
Publicado: (2013)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
por: Rafati, Mohammadreza, et al.
Publicado: (2022)

Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy
por: Senol, Sefika Pinar, et al.
Publicado: (2016)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Effects of oral iron chelator deferasirox on human malignant lymphoma cells
por: Choi, Jong Gwon, et al.
Publicado: (2012)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016)

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy
por: Salehi, Samie, et al.
Publicado: (2017)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
por: Saigo, Katsuyasu, et al.
Publicado: (2013)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

P1451: PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX: RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY
por: Veneziano, Mathilde, et al.
Publicado: (2023)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2020)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up
por: IMPROTA, SALVATORE, et al.
Publicado: (2013)

Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
por: Kim, Dae Sik, et al.
Publicado: (2016)

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease
por: Raj, Ashok, et al.
Publicado: (2022)

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2023)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
por: Ricchi, Paolo, et al.
Publicado: (2015)

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
por: Taher, Ali T., et al.
Publicado: (2018)

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation
por: Finkenstedt, Armin, et al.
Publicado: (2010)

Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells
por: Legendre, Claire, et al.
Publicado: (2016)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
por: Shinoda, Shuhei, et al.
Publicado: (2018)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
Publicado: (2019)

On‐demand treatment with the iron chelator deferasirox is ineffective in preventing blood‐induced joint damage in haemophilic mice
por: Pulles, Astrid E., et al.
Publicado: (2021)

Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort
por: Casale, Maddalena, et al.
Publicado: (2021)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
por: Harima, Hirofumi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1s4jsrmnedfdv93khi06162o4a